等待開盤 04-01 09:30:00 美东时间
+0.140
+1.49%
William Blair analyst Jason Ader downgrades AvePoint (NASDAQ:AVPT) from Outperform to Market Perform.
03-23 21:02
今日重点评级关注:HC Wainwright & Co.:维持Helus Pharma"买入"评级,目标价从55美元升至95美元;HC Wainwright & Co.:维持Compass Pathways"买入"评级,目标价从40美元升至70美元
03-03 20:22
今日重点评级关注:巴克莱:维持C4 Therapeutics"超配"评级,目标价从5美元升至7美元;富国银行:维持Agilon Health"超配"评级,目标价从1美元升至1.5美元
03-02 14:08
Evercore ISI Group analyst Kirk Materne maintains AvePoint (NASDAQ:AVPT) with a Outperform and lowers the price target from $18 to $14.
02-27 21:41
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据AvePoint业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **2025财年第四季度业绩:** - 总营收:1.147亿美元,同比增长29%,按固定汇率计算增长25% - SaaS营收:8,890万美元,同比增长37%,占总营收的78% - 服务营收:1,460万美元,同比增长20%,占总营收的13% - 毛利润:8,510万美元,毛利率74.2% - Non-GAAP营业利润:2,290万美元,营业利率20% - GAAP营业利率:7.9% - 自由现金流:8,160万美元(全年),现金流利率19% - 现金及现金等价物:4.8
02-27 12:28
华盛资讯2月27日讯,AvePoint, Inc. Class A公布2025财年年度业绩,公司年度营收4.19亿美元,同比增长27.0%,归母净利润0.35亿美元,扭亏为盈。
02-27 08:38
华盛资讯2月27日讯,AvePoint, Inc. Class A公布2025财年Q4业绩,公司Q4营收1.15亿美元,同比增长29.2%,归母净利润0.16亿美元,扭亏为盈。
02-27 06:36
AvePoint (NASDAQ:AVPT) sees Q1 sales of $115.000 million-$117.000 million vs $111.401 million analyst estimate.
02-27 06:31
The earnings results for AvePoint (NASDAQ:AVPT) for Q4 were made public on Thur...
02-27 05:08
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11